Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
Phys Med Biol ; 60(7): 3013-29, 2015 Apr 07.
Article in English | MEDLINE | ID: mdl-25789418

ABSTRACT

The purpose of this study was to assess the feasibility of proton pencil beam scanning (PBS) for the treatment of mediastinal lymphoma. A group of 7 patients of varying tumor size (100-800 cc) were planned using a PBS anterior field. We investigated 17 fractions of 1.8 Gy(RBE) to deliver 30.6 Gy(RBE) to the internal target volume (ITV). Spots with σ ranging from 4 mm to 8 mm were used for all patients, while larger spots (σ = 6-16 mm) were employed for patients with motion perpendicular to the beam (⩾5 mm), based on initial 4-dimensional computed tomography (4D CT) motion evaluation. We considered volumetric repainting such that the same field would be delivered twice in each fraction. The ratio of extreme inhalation amplitude and regular tidal inhalation amplitude (free-breathing variability) was quantified as an indicator of potential irregular breathing during the scanning. Four-dimensional dose was calculated on the 4D CT scans based on the respiratory trace and beam delivery sequence, implemented by partitioning the spots into separate plans on each 4D CT phase. Four starting phases (end of inhalation, end of exhalation, middle of inhalation and middle of exhalation) were sampled for each painting and 4 energy switching times (0.5 s, 1 s, 3 s and 5 s) were tested, which resulted in 896 dose distributions for the analyzed cohort. Plan robustness was measured for the target and critical structures in terms of the percent difference between 'delivered' dose (4D-evaluated) and planned dose (calculated on average CT). It was found that none of the patients exhibited highly variable or chaotic breathing patterns. For all patients, the ITV D98% was degraded by <2% (standard deviations âˆ¼ 0.1%) when averaged over the whole treatment course. For six out of seven patients, the average degradation of ITV D98% per fraction was within 5% . For one patient with motion perpendicular to the beam (⩾5 mm), the degradation of ITV D98% per fraction was up to 15%, which was mitigated to 2% by employing larger spots and repainting. Deviation of mean lung dose was at most 0.2 Gy(RBE) (less than 1% of prescribed dose, 30.6 Gy(RBE)), while the deviation of heart maximum dose and cord maximum dose could exceed 5% of the prescribed dose. No significant difference in either target coverage or normal tissue dose was observed for different energy switching times compared via two-sided Wilcoxon signed-rank tests (p < 0.05). This feasibility study demonstrates that, for mediastinal lymphoma, the impact of the interplay effect on the PBS plan robustness is minimal when volumetric repainting and/or larger spots are employed.


Subject(s)
Four-Dimensional Computed Tomography/methods , Lymphoma/diagnosis , Mediastinal Neoplasms/diagnosis , Radiotherapy Planning, Computer-Assisted/methods , Dose Fractionation, Radiation , Humans , Movement , Respiration , Tomography, X-Ray Computed/methods
2.
Med Phys ; 39(6Part8): 3687-3688, 2012 Jun.
Article in English | MEDLINE | ID: mdl-28518906

ABSTRACT

PURPOSE: Post-prostatectomy patients may be treated with endorectal balloon (ERB) placed during the radiation therapy. The objectives of this tudy are to investigate geometrical variation of organs at risk (OAR) and CTVs (based on RTOG and EORTC guidelines) throughout the course of radiation therapy and their dosimetric impact. METHODS: Six consecutive post-prostatectomy patients enrolled on a prospective IRB approved institutional study were analyzed. Patients underwent CT/MRI simulation and treatment with daily endorectal balloon (ERB). Six T2-MRI scans were performed during the treatment course. Bladder, rectum and two sets of CTVs according to the RTOG and EORTC guidelines were contoured by physician on each of the weekly MRI scans. The MRI scans were subsequently rigidly fused to the CT simulation images to simulate daily kV-kV patient alignment. RESULTS: 1. A consistent trend of decreasing bladder volume was found after the first week of treatment and therefore the V65Gy was found to increase after the second week of the treatment.2. The rectal volume with ERB was found to be relatively consistent during the treatment course. Displacements of rectal contours were within 2mm in all directions. The V60Gy<20% (our institutional rectal constraint) varied on average less than 2%.3. We found that the CTV volumes contoured per EORTC guideline exhibits a larger variation than those drawn according to the RTOG guidelines most likely due to the bladder exclusion imposed by it. While the average variation of RTOG based CTV volume was found within 5%, the variation of CTV-EROTC volumes was more then 10%) (p = 0.06). CONCLUSIONS: In post-prostatectomy patients undergoing radiotherapy with daily ERB had a consistent decrease in the bladder volume during the treatment leading to increased bladder irradiation and changes in the CTV volumes predominantly when EORTC guideline were followed.

3.
Bone Marrow Transplant ; 46(4): 475-84, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21113184

ABSTRACT

TBI has been used widely in the setting of BMT over the past 3 decades. Early research demonstrated feasibility and efficacy in the myeloablative setting, in preparation first for allogenic BMT and later for autologous stem cell rescue. As experience with TBI increased, its dual roles of myeloablation and immunosuppression came to be recognized. Toxicity associated with myeloablative TBI remains significant, and this treatment is generally reserved for younger patients with excellent performance status. Reduced intensity conditioning regimens may be useful to provide immunosuppression for patients who are not candidates for myeloablative treatment. Efforts to reduce toxicity through protection of normal tissue using methods of normal tissue blocking and use of TLI, rather than TBI, continue. In the future, modalities such as helical tomotherapy, proton radiotherapy and radioimmunotherapy, may have roles in delivery of radiation to the BM and lymphoid structures with reduced normal tissue toxicity. With further investigation, these efforts may expand the therapeutic ratio associated with TBI, allowing safer delivery to a broader range of patients.


Subject(s)
Bone Marrow Transplantation/methods , Hematopoietic Stem Cell Transplantation/methods , Whole-Body Irradiation/adverse effects , Whole-Body Irradiation/methods , Forecasting , Humans , Immunosuppression Therapy , Transplantation Conditioning/methods
4.
Neurology ; 59(1): 40-8, 2002 Jul 09.
Article in English | MEDLINE | ID: mdl-12105305

ABSTRACT

BACKGROUND: Assumptions about the damaging effects of radiotherapy (XRT) are based on studies in which total dose, dose fraction, treatment volume, degree of malignancy, chemotherapy, tumor recurrence, and neurologic comorbidity interact with XRT effects. This is a prospective, long-term study of XRT effects in adults, in which total dose and dose fraction were constrained and data related to tumor recurrence and neurologic comorbidity (e.g., hypertension) were excluded. METHODS: The effects of XRT on the cognitive and radiographic outcomes of 26 patients with low-grade, supratentorial, brain tumors yearly from baseline (6 weeks after surgery and immediately before XRT) and yearly to 6 years were examined. Radiographic findings were examined regionally. RESULTS: Selective cognitive declines (in visual memory) emerged only at 5 years, whereas ratings of clinical MRI (T2 images) showed mild accumulation of hyperintensities with post-treatment onset from 6 months to 3 years, with no further progression. White matter atrophy and total hyperintensities demonstrated this effect, with subcortical and deep white matter, corpus callosum, cerebellar structures, and pons accounting for these changes over time. About half of the patients demonstrated cognitive decline and treatment-related hyperintensities. CONCLUSIONS: There was no evidence of a general cognitive decline or progression of white matter changes after 3 years. Results argue for limited damage from XRT at this frequently used dose and volume in the absence of other clinical risk factors.


Subject(s)
Cognition Disorders/etiology , Radiotherapy/adverse effects , Supratentorial Neoplasms/radiotherapy , Adult , Cerebral Cortex/pathology , Cognition Disorders/pathology , Depression/diagnosis , Fatigue/diagnosis , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Neuropsychological Tests , Prospective Studies , Radiotherapy Dosage , Supratentorial Neoplasms/mortality , Supratentorial Neoplasms/pathology
10.
Ann Card Anaesth ; 2(2): 16-21, 1999 Jul.
Article in English | MEDLINE | ID: mdl-17846486

ABSTRACT

BACKGROUND: The functional derangements in the myocyte cell membrane, the sarcolemma, during short myocardial ischaemia and reperfusion are attributed to excessive influx of Ca2+ ions via the voltage-sensitive calcium channels (VSCC) and to the free radical-related injury. However, it is unclear whether the primary changes in the VSCC should be attributed to the ischaemic effect or to free radical action on channel constituents. Under these circumstances of ischaemia and reperfusion, volatile anaesthetics have exhibited protective properties on the myocardium. The present study is aimed at characterizing the effect of artificially-generated oxygen free radicals on the VSCC in canine sarcolemma, independently of the effect of ischaemia, and the effect of halothane on the membranes during the surge of the free radicals. METHODS: Selective production of free radicals (O2-, CO2-) was made by gamma irradiation of isolated sarcolemma membranes with 137 Cesium (Cs), in the presence of 20 mM sodium formate. Control studies were performed without formate in the aqueous solution. In an additional group, liquid halothane (3 microl. 1.9 vol%) was added to the sarcolemma / formate preparation immediately prior to irradiation. The effects of free radicals on the VSCC was evaluated by redioligand binding studies of the calcium channel blocker [3H] isradipine to the sarcolemma. RESULTS: In six control studies, the rediolytic aqueous species produced by 137 Cs irradiation resulted in unchanged [3 H] isradipine binding. In the presence of formate [n=9], the free radicals have caused a 23% to 25% decrease, both, in density and dissociation constant (P=0.05) of [3 H]isradipine to the VSCC binding sites. When superoxide radicals were generated in the presence of 1.9% halothane and formate (n=6), a significant increase in maximal binding capacity (by 55% +/- 2; P<0.01) and in the dissociation constant (by 209% +/- 35, P<0.01) occurred. CONCLUSION: Oxidative free radicals which are generated by gamma irradiation exerted minimal changes on the normal function of the VSCC as reflected by the non-significant changes in [3 H] isradipine specific binding. Introduction of halothane into free radical generating system causes acute perturbations to the VSCC kinetics, and does not provide protection to the cardiac membranes.

11.
Br J Haematol ; 89(3): 506-15, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7734348

ABSTRACT

One hundred and forty-six patients with acute leukaemia (81 with ANLL and 65 with ALL) received allogeneic bone marrow transplantation from their fully matched siblings. 121 patients underwent T-cell depletion (TCD) using Campath 1 monoclonal rat anti-human lymphocyte (CDw52) antibodies; 67 with Campath 1M and 54 with Campath 1G isotypes. Patients were conditioned for transplant using either total body irradiation combined with chemotherapy (125 patients) or busulfan and cyclophosphamide (21 patients). 112 recipients of T-cell depleted allografts received in addition total lymphoid irradiation (TLI) for prevention of rejection. Engraftment of neutrophils (> 0.5 x 10(9)/l) and platelets (> 25 x 10(9)/l) occurred on days 15 and 18, and on days 18 and 20 in recipients of Campath 1M and Campath 1G treated marrows respectively. Rejection was documented in 6.8% of T-cell depleted transplants. Leukaemia relapse-free survival at 2 years was 83% for patients transplanted in first CR, 76% in second CR (P2 = 0.34) and 42% in advanced leukaemia (P2 = 0.009). 81 marrow recipients, 38 with Campath 1M and 43 with Campath 1G treated marrow, received post-transplant graded increments of donor's peripheral blood lymphocytes (PBL) to induce graft-versus-leukaemia (GVL) effects. Administration of donor's PBL was associated with clinically significant GVHD and with decreased relapse rate especially in patients with ALL. Our data suggest that in patients receiving marrow allografts depleted of T cells by Campath 1 monoclonal antibodies, rejection can be reduced by adequate pregrafting immunosuppression. In patients with advanced disease, post-transplant cell-mediated immunotherapy (CMI) using donor's PBL may be beneficial; however, further studies are needed to define the optimal schedule of CMI for safe and effective prevention of relapse following TCD bone marrow transplantation in malignant haematological diseases.


Subject(s)
Antigens, Neoplasm , Bone Marrow Transplantation/methods , Glycoproteins , Leukemia/therapy , Lymphocyte Depletion/methods , Lymphocyte Transfusion , Acute Disease , Adolescent , Adult , Aged , Antigens, CD/immunology , CD52 Antigen , Child , Child, Preschool , Chronic Disease , Disease-Free Survival , Female , Graft Rejection , Graft Survival , Graft vs Host Disease/etiology , Humans , Immunity, Cellular , Immunoglobulin G/immunology , Immunoglobulin M/immunology , Immunotherapy/methods , Male , Middle Aged , Recurrence , T-Lymphocytes/immunology
12.
Ann Surg Oncol ; 1(1): 28-37, 1994 Jan.
Article in English | MEDLINE | ID: mdl-7834425

ABSTRACT

BACKGROUND: The management of pleural neoplasms, specifically mesothelioma, remains difficult. We performed a phase I trial in 54 patients with isolated hemithorax pleural malignancy to determine (a) the feasibility of intraoperative, intrapleural photodynamic therapy after debulking surgery; (b) the influence of light dose/sensitizer interval on postoperative morbidity in order to define the photodynamic therapy (PDT) maximal tolerated dose (MTD); and (c) whether first order dosimetry could be applied to this complex geometry. METHODS: Cohorts of three patients were given escalating intraoperative light doses of 15-35 J/cm2 48 h after i.v. delivery of 2.0 mg/kg Photofrin II (Quadra Logic Technologies, Vancouver, British Columbia, Canada), and then escalating light doses of 30-32.5 J/cm2 after a 24-h sensitizer/operation interval. Twelve patients could not be debulked to the prerequisite 5 mm residual tumor thickness. The remaining 42 patients underwent 19 modified pleuropneumonectomies, five lobectomy-pleurectomies, and 18 pleurectomies. Intrapleural PDT was delivered using 630 nm light from two argon pump-dye lasers, and real-time and cumulative light doses were monitored using seven uniquely designed, computer-interfaced photodiodes. RESULTS: There was one 30-day mortality from intraoperative hemorrhage. In the 48-h sensitizer/operation group (n = 33), possible PDT-related complications included an empyema with late hemorrhage in one of three patients at 17.5 J/cm2 and a bronchopleural fistula at 35 J/cm2. At each of these light doses, three additional patients were treated without complication. Two patients subjected to 24-h sensitizer dosing and 32.5 J/cm2 developed esophageal perforations after pleuropneumonectomy at identical sites. The MTD was declared as 30 J/cm2 light with a 24-h dosing interval when none of the six patients (three original, three repeat) at that level developed toxicity. CONCLUSIONS: These data demonstrate that resection and intrapleural PDT can be performed safely with currently available sensitizers and lasers. Phase II and III trials are now warranted at this MTD in a homogeneous population of patients with pleural malignancies.


Subject(s)
Photochemotherapy , Pleural Neoplasms/drug therapy , Adult , Aged , Combined Modality Therapy , Female , Humans , Male , Mesothelioma/drug therapy , Mesothelioma/mortality , Mesothelioma/surgery , Middle Aged , Photochemotherapy/adverse effects , Photochemotherapy/methods , Pleural Neoplasms/mortality , Pleural Neoplasms/surgery , Survival Rate
14.
Lasers Surg Med ; 14(2): 118-23, 1994.
Article in English | MEDLINE | ID: mdl-8183046

ABSTRACT

Surgery with intraoperative photodynamic therapy (PDT) has the potential to improve the treatment of pleural malignancies. Before embarking on such treatment in humans, however, thoracic tissue tolerance to PDT was studied. For each of three (1 week, 1 month, and 6 month) study end-points, one control (no Photofrin II [PII]) and four treated animals underwent thoracotomy 72 hours after I.V. injection (6 mg/kg) PII. Red light (630 nm) was delivered (5-40 J/cm2) to the pleural surface (1 cm diameter) of selected thoracic organs. No clinical differences were observed between PDT and control dogs. The control showed no histological changes; however, in the treated animals focal areas of coagulation necrosis were found at 1 week which progressed to fibrosis at 1 month. The extent and depth of injury was proportional to light dose. The lung was the most sensitive; the chest wall was the most resistant. Myocardium had superficial damage, whereas coronary arteries appeared normal. The results provide the basis for proceeding to phase I human trials in the evaluation of PDT as an intraoperative adjuvant treatment in the management of pleural malignancies.


Subject(s)
Dihematoporphyrin Ether/therapeutic use , Hematoporphyrin Photoradiation , Pleura/surgery , Pleural Neoplasms/drug therapy , Pleural Neoplasms/surgery , Animals , Combined Modality Therapy , Dihematoporphyrin Ether/adverse effects , Dogs , Female , Intraoperative Care , Male , Mesothelioma/drug therapy , Mesothelioma/surgery , Pleura/pathology , Thoracotomy
15.
J Pediatr ; 123(2): 269-72, 1993 Aug.
Article in English | MEDLINE | ID: mdl-8345425

ABSTRACT

We describe a 15-year-old boy with hemangiomatosis of bone and hypophosphatemic rickets. The rickets was ameliorated by irradiation of the skeletal lesions.


Subject(s)
Bone Neoplasms/radiotherapy , Hemangioma/radiotherapy , Rickets/radiotherapy , Tibia , Adolescent , Bone Neoplasms/complications , Bone Neoplasms/pathology , Hemangioma/complications , Hemangioma/pathology , Humans , Male , Remission Induction , Rickets/complications
16.
Int J Radiat Oncol Biol Phys ; 25(3): 445-57, 1993 Feb 15.
Article in English | MEDLINE | ID: mdl-8436523

ABSTRACT

PURPOSE: Phase I study designed to determine the maximum tolerated dose of intraoperative photodynamic therapy (PDT) at laparotomy/debulking surgery in patients with refractory or recurrent, disseminated intraperitoneal tumors. METHODS AND MATERIALS: Patients received dihematoporphyrin ethers (DHE) 1.5-2.5 mg/kg by i.v. injection prior to surgery. Patients resected to < or = 5 mm of residual disease underwent laser light delivery to all peritoneal surfaces. RESULTS: Fifty-four patients entered the study. Thirty-nine underwent resection and light delivery/PDT. PDT dose was escalated by increasing DHE from 1.5 to 2.5 mg/kg, shortening the interval between DHE injection and surgery from 72 to 48 hr, and increasing the light dose. Initially, 630 nm red light alone was used. In this group, PDT of 2.8-3.0 J/cm2 induced small bowel edema and resulted in 3 small bowel perforations after bowel resection or enterotomy. Further light dose escalation, however, was achieved by switching to less penetrating 514 nm green light to the bowel/mesentery. In later patients, whole peritoneal PDT was supplemented with boost doses of 10-15 J/cm2 red light or 5-7.5 J/cm2 green light to high risk areas. Small bowel complications were not seen after switching to less penetrating green light. Dose limiting toxicities occurred in 2 of 3 patients at the highest light dose of 5.0 J/cm2 green light with boost. These patients had pleural effusions that required thoracentesis and postoperative respiratory support for 7-9 days, while one had a gastric perforation. At potential follow-up times of 3.8-43.1 months (median 22.1 months), 30/39 patients are alive and 9/39 are free of disease. CONCLUSION: The maximum tolerated dose of intraoperative PDT following debulking surgery performed 48 hr after intravenous administration 2.5 mg/kg DHE is 3.75 J/cm2 of 514 nm green light to the entire peritoneal surface with boosts to 5.0-7.5 J/cm2 of 514 nm green light or 10-15 J/cm2 of 630 nm red light to sites of gross disease encountered at surgery.


Subject(s)
Carcinoma/therapy , Dihematoporphyrin Ether/administration & dosage , Ovarian Neoplasms/therapy , Peritoneal Neoplasms/therapy , Photochemotherapy , Sarcoma/therapy , Adult , Aged , Carcinoma/drug therapy , Carcinoma/surgery , Combined Modality Therapy , Female , Humans , Infusions, Intravenous , Male , Middle Aged , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/surgery , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/surgery , Photochemotherapy/adverse effects , Sarcoma/drug therapy , Sarcoma/surgery , Survival Rate
17.
Clin Pharmacol Ther ; 52(5): 518-27, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1424426

ABSTRACT

The power spectrum of instantaneous heart rate fluctuations was used to determine the optimal doses of atropine that induce a maximal vagolytic or vagomimetic effect. In a crossover placebo controlled study, eight volunteers received increasing bolus doses of intravenous atropine (0.1 to 2.3 mg per subject) or placebo, and frequency bands of the power spectrum were integrated. During atropine administration a significant bimodal dose dependence was observed for the respiratory peak (0.2 to 0.4 Hz, p = 0.0006), the midfrequency band (0.09 to 0.15 Hz, p = 0.0035), and mean heart rate (p < 0.0001). Low doses (< 0.4 mg per subject) increased the respiratory and midfrequency band power, with maximal response at 0.2 mg per subject. Larger doses of atropine, 0.5 to 2.3 mg per subject, markedly reduced the power in all frequency bands in a dose-dependent way. The corresponding changes in mean heart rate were simultaneous, but in the opposite direction. We suggest that the respiratory peak of the power spectrum can be used to optimize drug effects on cardiac parasympathetic control.


Subject(s)
Atropine/pharmacology , Heart Rate/drug effects , Parasympathetic Nervous System/drug effects , Adult , Atropine/administration & dosage , Dose-Response Relationship, Drug , Electrocardiography/drug effects , Electrocardiography/methods , Fourier Analysis , Heart/innervation , Humans , Male , Reference Values , Respiration/drug effects , Signal Processing, Computer-Assisted , Single-Blind Method
18.
Br J Clin Pharmacol ; 33(5): 507-10, 1992 May.
Article in English | MEDLINE | ID: mdl-1524963

ABSTRACT

1. The value of low dosage of pyridostigmine (30 mg three times daily) in preventing peripheral anti-muscarinic side effects of a transdermal controlled-release formulation of hyoscine, was tested in a double-blind placebo-controlled study, involving 47 healthy subjects. 2. Salivary excretion was repeatedly measured during 48 h of combined therapy of two transdermal hyoscine patches with pyridostigmine and 14 h after its cessation. Blood acetylcholinesterase activity was also measured, serving as an index of pyridostigmine bioavailability. 3. The adjunctive therapy with pyridostigmine was highly effective in preventing the substantial impairment in salivary flow caused by the transdermal formulation. An associated 23% inhibition of blood acetylcholinesterase activity was observed. 4. Small doses of pyridostigmine may therefore have a role in increasing the tolerability of transdermal hyoscine therapy. In some patients this drug combination might also allow some increment of the hyoscine dose.


Subject(s)
Acetylcholinesterase/blood , Pyridostigmine Bromide/pharmacology , Salivation/drug effects , Scopolamine/adverse effects , Administration, Cutaneous , Adolescent , Adult , Delayed-Action Preparations , Double-Blind Method , Drug Therapy, Combination , Humans , Pyridostigmine Bromide/administration & dosage , Scopolamine/administration & dosage , Tablets
19.
Cancer Res ; 52(7): 1750-3, 1992 Apr 01.
Article in English | MEDLINE | ID: mdl-1551104

ABSTRACT

Nitroxide compounds are stable free radicals which were previously investigated as hypoxic cell radiosensitizers. The stable nitroxide 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (Tempol) has recently been shown to protect aerated cells in culture against superoxide generated from hypoxanthine/xanthine oxidase, hydrogen peroxide, and radiation-induced cytotoxicity and to modestly sensitive hypoxic cultured cells. To extend these observations from the cellular level to the whole animal, the toxicity, pharmacology, and in vivo radioprotective effects of Tempol were studied in C3H mice. The maximum tolerated dose of Tempol administered i.p. was found to be 275 mg/kg, which resulted in maximal Tempol levels in whole blood 5-10 min after injection. Mice were exposed to whole-body radiation in the absence or presence of injected Tempol (275 mg/kg) 5-10 min after administration. Tempol treatment provided significant radioprotection (P less than 0.0001); the dose of radiation at which 50% of Tempol-treated mice die at 30 days was 9.97 Gy, versus 7.84 Gy for control mice. Tempol represents a new class of in vivo, non-sulfur-containing radiation protectors. Given the potential for hypoxic radiosensitization and aerobic cell radioprotection, Temporal or other analogues may have potential therapeutic application.


Subject(s)
Cyclic N-Oxides/pharmacology , Radiation-Protective Agents/pharmacology , Animals , Cyclic N-Oxides/pharmacokinetics , Cyclic N-Oxides/toxicity , Dose-Response Relationship, Radiation , Female , Free Radicals , Metabolic Clearance Rate , Mice , Mice, Inbred C3H , Spin Labels , Time Factors , Whole-Body Irradiation
20.
Int J Radiat Oncol Biol Phys ; 22(1): 65-9, 1992.
Article in English | MEDLINE | ID: mdl-1309205

ABSTRACT

The tolerance of mediastinal structures to intraoperative radiotherapy (IORT) was investigated in 3 separate animals trials using 49 adult foxhounds and one limited Phase I trial in 4 patients with Stage II or III non-small cell lung cancer (NSCLC). The 1- to 2-year results of these trials have been previously reported with significant toxicity found at dose levels over 20 Gy. We now report the results of five dogs reserved for long term studies and one Stage II NSCLC patient alive at 5 years. Two dogs received 20 Gy IORT and one received 30 Gy IORT to the esophagus, all three to a single 6 cm field with 9 MeV electrons. One control dog underwent surgery without irradiation. One dog received 20 Gy IORT to a single 5 cm mediastinal field with 13 MeV electrons following left pneumonectomy. At 5 years, all five dogs reserved for a long term evaluation were alive and evaluable with minimal endoscopic and radiographic abnormalities. The one patient alive at 5 years for evaluation received 25 Gy IORT to two matched 6 cm fields with 13 MeV electrons. She has stable dyspnea on exertion and there is no evidence of cancer by endoscopy. We conclude, based on these limited data, that IORT in the mediastinum may be safe at dose levels that do not exceed 20 Gy, and further careful evaluation at these lower treatment doses is warranted to determine efficacy.


Subject(s)
Carcinoma, Non-Small-Cell Lung/radiotherapy , Esophagus/radiation effects , Lung Neoplasms/radiotherapy , Lung/radiation effects , Mediastinum/radiation effects , Animals , Bronchi/radiation effects , Dogs , Follow-Up Studies , Humans , Intraoperative Period , Pneumonectomy
SELECTION OF CITATIONS
SEARCH DETAIL
...